Department of Pharmacology & Chemical Biology at the University of Pittsburgh
Veronica Alonso, PhD
Adjunct Assistant Professor
2.11 School of Medicine, Universidad San Pablo-CEU, Avenida Monteprincipe S/N
Madrid, Spain 28660

Email:
veronica.alonsorodriguez@ceu.es
Phone: 0034 91 372 4700


Education
B.S. and M.S. (Biology and Biomedicine), Universidad Complutense de Madrid, Spain, 2003
Ph.D. (Biochemistry, Biomedicine and Molecular Biology), Universidad Autonoma de Madrid, Spain, 2008
Postdoctoral Fellow (Bone and Mineral Metabolism), Jimenez Diaz Foundation, Madrid, Spain, 2008


Research Areas
Signal Transduction
Photo of Veronica Alonso, PhD

Dr. Alonso┬┤s research is currently focusing on the pro-metastatic changes in organs where metastases later appear. Such changes involve the formation of pre-metastatic niches that favor the establishment of circulating tumor cells with an organ-mimetic phenotype -a functional requirement for the niche-. The goal of these studies is to identify the pathogenic implications of bone pre-metastatic niche-stimulating factors and the tumor osteomimetism (OMT) in preclinical and clinical models of prostate and breast cancer. Techniques applied include cell culture, rat and mouse animal models, biochemical, proteomics, Real Time-PCR and microscopy approaches. Also, Dr Alonso is focused on the study of parathyroid hormone (PTH) receptor signaling in bone and cancer.

 





Important Publications
Song GJ, S Barrick, KL Leslie, PM Bauer, V Alonso, PA Friedman, NM Fiaschi-Taesch and A Bisello.  The scaffolding protein EBP50 promotes vascular smooth muscle cell proliferation and neointima formation by regulating Skp2 and p21 (cip1).  Arterioscler Thromb Vasc Biol 32:33-41, 2012.
Alonso V, CE Magyar, B Wang, A Bisello and PA Friedman.  Ubiquitination-deubiquitination balance dictates ligand-stimulated PTHR sorting.  J Bone Miner Res 26:2923-2934, 2011.
Alonso V, JA Ardura, B Wang, WB Sneddon and PA Friedman.  A naturally occurring isoform inhibits parathyroid hormone receptor trafficking and signaling.  J Bone Miner Res 26:143-155, 2011.
Alonso V, FC Perez-Martinez, FJ Calahorra and P Esbrit.  Phytoestrogen modulation of bone-related cytokines and its impact on cell viability in human prostate cancer cells.  Life Sci 85:421-430, 2009.
Alonso V, AR de Gortazar, JA Ardura, I Andrade-Zapata, MV Alvarez-Arroyo and P Esbrit.  Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2.  J Cell Physiol 217:717-727, 2008.
Perez-Martinez FC, V Alonso,JL Sarasa, F Manzarbeitia, R Vela-Navarrete, FJ Calahorra and P Esbrit.  Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma.  Histol Histopathol 23:709-715, 2008. 
de Gortazar AR, V Alonso, MV Alvarez-Arroyo and P Esbrit.  Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro.  Calcif Tissue Int 79:360-369, 2006.




Back to Top